Yes, WRN helicase is considered a potential therapeutic target, particularly in cancers with WRN deficiencies. Inhibitors of WRN helicase may selectively kill cancer cells by exacerbating their existing DNA repair defects, a concept known as synthetic lethality. This approach is being explored in preclinical studies.
